India Clears Its First Dengue Vaccine, Opening a New Front Against a Mosquito-Borne Scourge

India has approved its first dengue vaccine, clearing Takeda's Qdenga for public use in a country that carries one of the world's heaviest burdens of the mosquito-borne disease. The Central Drugs Standard Control Organisation granted market authorisation on July 20, opening the way for a long-sought tool against an illness that sickens millions of Indians each monsoon season.

The approval covers people aged 4 to 60 and, crucially, does not require pre-vaccination testing to confirm a prior dengue infection — a limitation that had complicated the rollout of an earlier vaccine elsewhere. Qdenga, also known as TAK-003, is given as two doses three months apart and is designed to protect against all four serotypes of the dengue virus, any of which can cause the high fevers, joint pain and, in severe cases, life-threatening complications that give the disease its nickname "breakbone fever."

Dengue has surged across South Asia in recent years as warming temperatures and rapid urbanization expand the range of the Aedes mosquitoes that spread it. India records hundreds of thousands of reported cases annually, and public-health experts believe the true toll is far higher because many infections go undiagnosed. Hospitals in major cities are routinely overwhelmed during outbreaks, and there has never been a specific treatment — only supportive care to manage symptoms.

Qdenga is not new to the world: more than 24 million doses have already been administered across 42 countries, including the European Union, the United Kingdom, Switzerland and Indonesia, and the World Health Organization has prequalified the product, confirming it meets international standards for quality, safety and efficacy. Bringing it to India, home to more than a billion people living in dengue-endemic regions, represents one of the largest potential markets for the shot.

Takeda said it is working with the Hyderabad-based company Biological E to scale up production inside India, a move aligned with the government's "Make in India" push to manufacture vaccines domestically for both local use and export. Local production could help hold down costs and ease the supply constraints that often hamper vaccine campaigns in low- and middle-income countries.

A private-market rollout is expected in early 2027, though officials have not finalized pricing or decided whether the vaccine will be folded into government immunization programs. Public-health advocates cautioned that a vaccine alone will not defeat dengue, which still demands mosquito control, surveillance and public awareness. But for a country that has watched the disease climb year after year, the approval marks a turning point — the first time India can offer its people a shot to fend off an infection that has long arrived with the rains.